Genzen is thrilled to announce the appointment of two highly accomplished medical professionals, Susan D’Costa, Ph.D., as Chief Technology Officer and Nicole O’Brien, Ph.D., as Chief Commercial Officer. With their extensive experience in gene and cell therapy contract development and manufacturing, they are perfectly poised to take Genzen to the next level as a premier CDMO.
Dr. D’Costa and Dr. O’Brien bring their impressive expertise in gene and cell therapy manufacturing to the Genezen leadership team! With over 25 years of experience in molecular virology, Dr. D’Costa will now be a driving force in AAV manufacturing as CTO. She has a wealth of knowledge in the CDMO and product side of gene and cell therapy, and brings her sage experience from Florida Biologix, Brammer Bio, Thermo Fisher Scientific, and Alcyone Therapeutics to the Genezen business unit.
Nicole O’Brien is a highly experienced and knowledgeable figure in the manufacturing industry. She has excelled in her career, having most recently occupied senior commercial leadership roles at Thermo Fisher Scientific, Brammer Bio, and FujiFilm Diosynth, where she has worked to design and implement innovative manufacturing programs.
Genezen is thrilled to have added world-renowned gene and cell therapy manufacturing experts Drs. D’Costa and O’Brien to its team! With their vast experience, both formally and informally, the entire Genezen team is excited for the contribution the experts will bring to the business’s growth trajectory. As President and CEO of Genezen, Steve Favaloro can’t wait to see what the future holds for the company and looks forward to what the doctors can add to the team!
Genezen’s exciting vision to become a leader in development and manufacturing services of retroviral, AAV and lentiviral vectors is soon to become a reality. With the construction of a brand-new cGMP multi-vector production facility in Fishers, Indiana set to be completed in 2022, Genezen is now accelerating its current growth through two new high-profile additions to its leadership team. With a decade of experience in viral vector manufacturing, Genezen is on the brink of achieving its goal to become a major player in the industry.
D’Costa is ecstatic to be taking on the role of Chief Technology Officer at Genezen. With her love of building gene therapy CMC frameworks from the start, she is excited to bring her knowledge to the forefront. Thanks to Genezen’s ability to create novel AAV vector production techniques as well as their extensive expertise inLV and RV vectors, D’Costa is more than determined to make a real impact.
Dr. O’Brien is thrilled to become Chief Commercial Officer of Genezen during an exciting period of growth. With its outstanding technical and operational team, Genezen is well-positioned to help customers with their complicated manufacturing needs. By steering the commercial strategy and execution, Dr. O’Brien is in a unique position to make a major impact on Genezen’s success.
Genezen has been at the forefront of the rapid expansion of the gene and cell therapy market for the past decade. As a leading contract development and manufacturing organization (CDMO), we take a science-first approach and strive to develop scalable, high-yield manufacturing processes and best-in-class technologies.
We invest regularly in a multi-location footprint, strategically located close to the most advanced modality hubs, so that we can better serve the needs of innovative gene and cell therapy companies. Our team of highly experienced professionals is dedicated to ensuring that you receive the highest quality of service and products.